Peer Review History

Original SubmissionSeptember 30, 2024
Decision Letter - Marcello Iriti, Editor

PONE-D-24-36320The effect of melatonin supplementation on the plasma levels of 2-arachidonoylglycerol, ghrelin and hedonic eating intensity in overweight/obese females: a study protocol for a pilot randomized controlled trialPLOS ONE

Dear Dr. Pourghassem Gargari,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 29 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Marcello Iriti, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

The funding for the trial received support from Tabriz University of Medical Sciences under grant number IR.TBZMED.REC.1402.075.

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

This protocol is the second phase of a Ph.D. dissertation registered at Tabriz University of Medical Sciences, Tabriz, Iran, with the registration number IR.TBZMED.REC.1402.075.

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

The funding for the trial received support from Tabriz University of Medical Sciences under grant number IR.TBZMED.REC.1402.075.

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1:  The authors intend to conduct a randomized, double-blinded, placebo-controlled study to investigate the effect of melatonin supplementation on plasma levels of 2-arachidonylglycerol and ghrelin, and intensity of hedonic eating. They will recruit forty-six women, randomly assigned to two arms: melatonin supplement or placebo with balanced design for 8 weeks. Data will be analyzed with ANCOVA.

1. Line 101. “46 subjects (23 in each group)”. The determined sample size seems quite arbitrary. What effect size can be detected by this sample size?

2. Line 114. “apparently healthy volunteers”. This sounds very subjective. Need to clarify how to define apparently healthy.

3. Line 148. “if any adverse events occur, unblinding is allowed”. Please clarify whether these participants will be included in the analysis.

4. Line 233. “log transformation will be applied to normalize variable”. As you do not know the distribution of variables yet, how do you know log-transformation will be appropriate?

Reviewer #2:  Dear Editor,

Thank you for inviting me to review this manuscript. I appreciate the opportunity to contribute to the peer review process for this study

General comments : The study makes a valuable contribution by investigating the effects of melatonin on hedonic eating in overweight/obese women, addressing an important gap in the literature. The introduction provides a strong background and context, with a clear and logical flow that lays a solid foundation for the research and leads smoothly to the study's main objective. The study design is robust, and the intervention plan is clearly defined. However, since the manuscript does not present any results, it limits the ability to fully evaluate the outcomes and implications of the research. Despite this, I believe this is an excellent study that could provide meaningful insights into the role of melatonin in eating behavior. However, there are some improvements that should be made prior to publishing.

Point 1 #In the introduction section, I suggest adding a line or two to briefly describe the PFS and explain its specific relevance to hedonic eating studies.

Point 2 # Could you clarify how the number of 46 participants was determined? It would be helpful to provide more details on how the sample size was calculated, and whether a power analysis was conducted. Also, please explain how the 15% attrition rate was estimated.

Point 2 # While you have have outlined a comprehensive set of inclusion and exclusion criteria, it’s still unclear how these have been verified during screening.

Point 3 #The block size is mentioned as two. It might be helpful to confirm that this approach maintains the required balance across groups, as the small block size may not provide sufficient flexibility to ensure even distribution, particularly toward the end of the randomization process.

Point 4# It’s good that one author (RM) created the randomization sequence without being involved in assigning participants. This could be even stronger if it’s mentioned whether they are also blinded to any participant details or baseline data to reduce bias further.

Point 5 # Please specify the software used for randomization.

Point 6# Specify the purpose of bi-weekly follow-up calls.

Point 7# Please clarify if there’s a standard method for counting and recording any unused tablets at each checkpoint to help ensure accurate tracking of compliance.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Revision 1

Dear Dr. Marcello Iriti,

Thank you very much for your comments on our manuscript entitled as: The effect of melatonin supplementation on the plasma levels of 2-arachidonoylglycerol, ghrelin and hedonic eating intensity in overweight/obese females: a study protocol for a pilot randomized controlled trial; Manuscript ID: PONE-D-24-36320. We really appreciate your time and consideration. The following are our point-by-point responses to the comments. We have highlighted all changes in the new format of the manuscript.

REVIEWER REPORT(S):

Referee: 1

Comments to the Author

-) Line 101. “46 subjects (23 in each group)”. The determined sample size seems quite arbitrary. What effect size can be detected by this sample size?

As noted in p.6, lines 121-127 currently, no human studies have investigated the use of melatonin supplementation on hedonic eating. The proposed study is a pilot project; its main aim is to establish data for sample size calculations for a larger trial. Various studies recommend a total sample size of at least 24 participants for a two-arm trial. Considering the sample size of previous studies on melatonin supplementation in overweight and obese Iranian women (Mohammadi et al, https://doi.org/10.1155/2021/3502325, and Mesri Alamdari et al, http://dx.doi.org/ 10.1055/s-0034-1384587) and to increase the accuracy and power of the study, in this clinical trial, we plan to enroll 40 participants, which, with a 15% attrition rate, will increase to 46 subjects (23 in each group).

-) Line 114. “apparently healthy volunteers”. This sounds very subjective. Need to clarify how to define apparently healthy.

Apparently healthy volunteers are individuals who have not been diagnosed with any medical conditions and are not taking any medications (p.7, lines: 140-141).

-) Line 148. “if any adverse events occur, unblinding is allowed”. Please clarify whether these participants will be included in the analysis.

If dropout rates reach 15% or higher due to adverse effects, we will conduct an intention-to-treat (ITT) analysis (p.9, lines: 175-176).

-) Line 233.“log transformation will be applied to normalize variable”. As you do not know the distribution of variables yet, how do you know log-transformation will be appropriate?

It was changed to: The normality of data distribution will be checked using the Kolmogorov-Smirnov test, and an appropriate method will be applied to normalize variables that do not follow a normal distribution (p.13, lines: 272-274).

Referee: 2

Comments to the Author

-) Suggestion adding a line or two to describe the PFS briefly In the introduction section

It was added to manuscript (p.5, lines: 92-94).

-) Could you clarify how the number of 46 participants was determined? It would be helpful to provide more details on how the sample size was calculated, and whether a power analysis was conducted. Also, please explain how the 15% attrition rate was estimated.

As noted in p.6, lines 121-127 currently, no human studies have investigated the use of melatonin supplementation on hedonic eating. The proposed study is a pilot project; its main aim is to establish data for sample size calculations for a larger trial. Various studies recommend a total sample size of at least 24 participants for a two-arm trial. Considering the sample size of previous studies on melatonin supplementation in overweight and obese Iranian women (Mohammadi et al, https://doi.org/10.1155/2021/3502325, and Mesri Alamdari et al, http://dx.doi.org/ 10.1055/s-0034-1384587) and to increase the accuracy and power of the study, in this clinical trial, we plan to enroll 40 participants, which, with a 15% attrition rate, will increase to 46 subjects (23 in each group). Regarding the attrition rate, the dropout rate can be determined using historical data from similar studies or pilot studies. A common rule of thumb is to assume a 10-20% dropout rate (Patel et al, DOI:10.55489/njcm.150620243815). Studies conducted on melatonin supplementation in Iran (such as Mohammadi et al, https://doi.org/10.1155/2021/3502325, Mesri Alamdari et al, http://dx.doi.org/ 10.1055/s-0034-1384587, Jamilian et al, https://doi.org/10.3389/fendo.2019.00273, Shabani et al, https://doi.org/10.1016/j.jad.2019.02.066, Bahrami et al, https://doi.org/10.1108/NFS-012019-0018, Bahrami et al, https://doi.org/10.1016/j.ctim.2020.102452, Pakravan et al, https://doi.org/10.4103/2277-9175.204593) found a maximum rate of 12.5%. Therefore, we have decided to consider the attrition rate to be 15%.

-) While you have outlined a comprehensive set of inclusion and exclusion criteria, it’s still unclear how these have been verified during screening.

As mentioned in the lines 129-131, the present pilot study is the second phase of a Ph.D. dissertation. The first phase of the project is cross-sectional, and approximately 400 overweight or obese females will be recruited. The mentioned inclusion and exclusion criteria will be assessed in the first phase of the project (p.7, lines: 151-153).

-) The block size is mentioned as two. It might be helpful to confirm that this approach maintains the required balance across groups, as the small block size may not provide sufficient flexibility to ensure even distribution, particularly toward the end of the randomization process.

We will change the block size to four (p.8, lines 164-165).

-) It’s good that one author (RM) created the randomization sequence without being involved in assigning participants. This could be even stronger if it’s mentioned whether they are also blinded to any participant details or baseline data to reduce bias further.

We applied this suggestion (p.9, line 180).

-) Please specify the software used for randomization.

Randomization is conducted using the Random Allocation Software (RAS). It is mentioned in p.8, lines 163-164.

-) Specify the purpose of bi-weekly follow-up calls.

We changed this phrase to: weekly follow-up calls to improve response rates and fewer dropouts (p.9, lines 189-190).

-) Please clarify if there’s a standard method for counting and recording any unused tablets at each checkpoint to help ensure accurate tracking of compliance.

The total intake of tablets for each subject is calculated by subtracting the number of tablets unused from the number of tablets dispensed (p.9, lines 195-196).

With Regards,

Reza Mahdavi

Nutrition Research Center, Department of Biochemistry and Diet Therapy, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran

Email: mahdavir@tbzmed.ac.ir

Bahram Pourghassem Gargari

Nutrition Research Center, Department of Biochemistry and Diet Therapy, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran

Email: pourghassemb@tbzmed.ac.ir

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Marcello Iriti, Editor

The effect of melatonin supplementation on the plasma levels of 2-arachidonoylglycerol, ghrelin and hedonic eating intensity in overweight/obese females: a study protocol for a pilot randomized controlled trial

PONE-D-24-36320R1

Dear Dr. Pourghassem Gargari,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Marcello Iriti, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for addressing the raised comments and made the edits accordingly. This reviewer has no further concern.

Reviewer #2: Dear Editor,

Thank you again for inviting me to review the revised manuscript for your esteemed journal.

The manuscript, titled « The effect of melatonin supplementation on the plasma levels of 2- arachidonoylglycerol, ghrelin and hedonic eating intensity in overweight/obese females: a study protocol for a pilot randomized controlled trial » (Manuscript ID: PONE-D-24-36320R1)," by Malihe Karamizadeh et al., has been appropriately revised. The authors have adequately addressed all the concerns raised. I find the revised manuscript to be well-prepared and scientifically robust. Therefore, I believe it merits publication in PLOS One.

Dear Authors, I have no further comments. Thank you for your efforts in addressing the previous concerns.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Marcello Iriti, Editor

PONE-D-24-36320R1

PLOS ONE

Dear Dr. Pourghassem Gargari,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Marcello Iriti

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .